12624 The Efficacy Of Glp1 Receptor Agonists As Adjunct Therapy To Insulin In Patients With Type 1 Diabetes: A Meta-analysis

Abstract Disclosure: M. Abi Azar: None. F. Harb: None. L.B. Nakhoul: None. N.F. Nakhoul: None. Rationale GLP1 receptor agonists are a class of antidiabetic that are well established in type 2 diabetes. While their efficacy in type 1 diabetes remains uncertain, this meta-analysis aims at evaluating the benefits of adding GLP1-RAs to insulin in patients with type 1 diabetes. The goal is to summarize advantages and drawbacks from updated existing literature. Objectives This study aims to evaluate the effects of adding GLP-1 receptor agonists to insulin therapy for type 1 diabetes, focusing on blood sugar control, body weight, insulin needs, and cardiovascular safety. It will analyze updated existing literature to assess the benefits and risks of this dual treatment approach. Search methods We searched PubMed, Medline, Scopus and Cochrane Library for relevant studies using keywords related to GLP-1 agonists, insulin, and type 1 diabetes. Eligibility criteria The study necessitates randomized controlled trials (RCTs) that compare GLP-1 RAs receptor agonists plus insulin versus insulin plus placebo in patients with type 1 diabetes, regardless of age or gender. Primary outcomes focus on HbA1c, with secondary outcomes evaluating changes in body weight, insulin requirements, systolic blood pressure, and Heart rate. Synthesis methods All statistical analyses were conducted using the Revman web software developed by Cochrane, and a p-value <0.05 will be considered statistically significant. Synthesis of results The analysis of 12 studies (1570 patients) showed GLP-1 RAs added to insulin reduced HbA1C significantly -0.3 % [-0.43--0.17], suggesting efficacy in type 1 diabetes. However, moderate to significant heterogeneity and bias were observed. GLP-1 RAs also led to a -4.6 Kg [-4.64, -4.57] greater weight reduction and lower insulin needs -4.32 IU[-4.38,-4.24], with a consistent reduction in SBP but an increase in heart rate. Conclusion: This meta-analysis of 12 studies with 1567 participants shows significant benefits of GLP-1 RA therapy in type 1 diabetes management but highlights the need to tailor treatments and explore further due to identified heterogeneity. Presentation: 6/2/2024